 | • レポートコード：MRC2-11QY11876 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は癲癇治療のグローバル市場について調査・分析したレポートです。種類別（第一世代、第二世代）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別癲癇治療の競争状況、市場シェア ・世界の癲癇治療市場：種類別市場規模 2015年-2020年（第一世代、第二世代） ・世界の癲癇治療市場：種類別市場規模予測 2021年-2026年（第一世代、第二世代） ・世界の癲癇治療市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界の癲癇治療市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米の癲癇治療市場分析：米国、カナダ ・ヨーロッパの癲癇治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの癲癇治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の癲癇治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの癲癇治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abbott Laboratories、GlaxoSmithKline Plc、UCB、Cephalon、Johnson & Johnson、Pfizer、Novartis AG、Abbvie、Janssen Pharmaceuticals、Sunovion Pharmaceuticals、Bausch Health、Sanofi S.A、Takeda、Eisai、F. Hoffmann-La Roche ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
In terms of geography, the Americas led the global epilepsy therapeutic market and is likely to hold close to 50% of the revenue market shares. The growth of this market in the region is due to the high prevalence of the disorder and the availability of treatment options in the region, especially in the developed markets such as the US and Canada.
Market Analysis and Insights: Global Epilepsy Therapeutic Market
The global Epilepsy Therapeutic market size is projected to reach US$ 4203 million by 2026, from US$ 4064.1 million in 2020, at a CAGR of 3.2%% during 2021-2026.
Global Epilepsy Therapeutic Scope and Market Size
Epilepsy Therapeutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Epilepsy Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Abbott Laboratories
GlaxoSmithKline Plc
UCB
Cephalon
Johnson & Johnson
Pfizer
Novartis AG
Abbvie
Janssen Pharmaceuticals
Sunovion Pharmaceuticals
Bausch Health
Sanofi S.A
Takeda
Eisai
F. Hoffmann-La Roche
Market segment by Type, the product can be split into
First Generation
Second Generation
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Epilepsy Therapeutic Revenue
1.4 Market by Type
1.4.1 Global Epilepsy Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 First Generation
1.4.3 Second Generation
1.5 Market by Application
1.5.1 Global Epilepsy Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Epilepsy Therapeutic Market Perspective (2015-2026)
2.2 Global Epilepsy Therapeutic Growth Trends by Regions
2.2.1 Epilepsy Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Epilepsy Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 Epilepsy Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Epilepsy Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key Epilepsy Therapeutic Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Epilepsy Therapeutic Players by Market Size
3.1.1 Global Top Epilepsy Therapeutic Players by Revenue (2015-2020)
3.1.2 Global Epilepsy Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global Epilepsy Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Epilepsy Therapeutic Market Concentration Ratio
3.2.1 Global Epilepsy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Epilepsy Therapeutic Revenue in 2019
3.3 Epilepsy Therapeutic Key Players Head office and Area Served
3.4 Key Players Epilepsy Therapeutic Product Solution and Service
3.5 Date of Enter into Epilepsy Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Epilepsy Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Epilepsy Therapeutic Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Epilepsy Therapeutic Market Size by Application (2015-2020)
5.2 Global Epilepsy Therapeutic Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Epilepsy Therapeutic Market Size (2015-2020)
6.2 Epilepsy Therapeutic Key Players in North America (2019-2020)
6.3 North America Epilepsy Therapeutic Market Size by Type (2015-2020)
6.4 North America Epilepsy Therapeutic Market Size by Application (2015-2020)
7 Europe
7.1 Europe Epilepsy Therapeutic Market Size (2015-2020)
7.2 Epilepsy Therapeutic Key Players in Europe (2019-2020)
7.3 Europe Epilepsy Therapeutic Market Size by Type (2015-2020)
7.4 Europe Epilepsy Therapeutic Market Size by Application (2015-2020)
8 China
8.1 China Epilepsy Therapeutic Market Size (2015-2020)
8.2 Epilepsy Therapeutic Key Players in China (2019-2020)
8.3 China Epilepsy Therapeutic Market Size by Type (2015-2020)
8.4 China Epilepsy Therapeutic Market Size by Application (2015-2020)
9 Japan
9.1 Japan Epilepsy Therapeutic Market Size (2015-2020)
9.2 Epilepsy Therapeutic Key Players in Japan (2019-2020)
9.3 Japan Epilepsy Therapeutic Market Size by Type (2015-2020)
9.4 Japan Epilepsy Therapeutic Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Epilepsy Therapeutic Market Size (2015-2020)
10.2 Epilepsy Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Epilepsy Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia Epilepsy Therapeutic Market Size by Application (2015-2020)
11 India
11.1 India Epilepsy Therapeutic Market Size (2015-2020)
11.2 Epilepsy Therapeutic Key Players in India (2019-2020)
11.3 India Epilepsy Therapeutic Market Size by Type (2015-2020)
11.4 India Epilepsy Therapeutic Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Epilepsy Therapeutic Market Size (2015-2020)
12.2 Epilepsy Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America Epilepsy Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America Epilepsy Therapeutic Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Abbott Laboratories
13.1.1 Abbott Laboratories Company Details
13.1.2 Abbott Laboratories Business Overview
13.1.3 Abbott Laboratories Epilepsy Therapeutic Introduction
13.1.4 Abbott Laboratories Revenue in Epilepsy Therapeutic Business (2015-2020))
13.1.5 Abbott Laboratories Recent Development
13.2 GlaxoSmithKline Plc
13.2.1 GlaxoSmithKline Plc Company Details
13.2.2 GlaxoSmithKline Plc Business Overview
13.2.3 GlaxoSmithKline Plc Epilepsy Therapeutic Introduction
13.2.4 GlaxoSmithKline Plc Revenue in Epilepsy Therapeutic Business (2015-2020)
13.2.5 GlaxoSmithKline Plc Recent Development
13.3 UCB
13.3.1 UCB Company Details
13.3.2 UCB Business Overview
13.3.3 UCB Epilepsy Therapeutic Introduction
13.3.4 UCB Revenue in Epilepsy Therapeutic Business (2015-2020)
13.3.5 UCB Recent Development
13.4 Cephalon
13.4.1 Cephalon Company Details
13.4.2 Cephalon Business Overview
13.4.3 Cephalon Epilepsy Therapeutic Introduction
13.4.4 Cephalon Revenue in Epilepsy Therapeutic Business (2015-2020)
13.4.5 Cephalon Recent Development
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Details
13.5.2 Johnson & Johnson Business Overview
13.5.3 Johnson & Johnson Epilepsy Therapeutic Introduction
13.5.4 Johnson & Johnson Revenue in Epilepsy Therapeutic Business (2015-2020)
13.5.5 Johnson & Johnson Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Epilepsy Therapeutic Introduction
13.6.4 Pfizer Revenue in Epilepsy Therapeutic Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 Novartis AG
13.7.1 Novartis AG Company Details
13.7.2 Novartis AG Business Overview
13.7.3 Novartis AG Epilepsy Therapeutic Introduction
13.7.4 Novartis AG Revenue in Epilepsy Therapeutic Business (2015-2020)
13.7.5 Novartis AG Recent Development
13.8 Abbvie
13.8.1 Abbvie Company Details
13.8.2 Abbvie Business Overview
13.8.3 Abbvie Epilepsy Therapeutic Introduction
13.8.4 Abbvie Revenue in Epilepsy Therapeutic Business (2015-2020)
13.8.5 Abbvie Recent Development
13.9 Janssen Pharmaceuticals
13.9.1 Janssen Pharmaceuticals Company Details
13.9.2 Janssen Pharmaceuticals Business Overview
13.9.3 Janssen Pharmaceuticals Epilepsy Therapeutic Introduction
13.9.4 Janssen Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2015-2020)
13.9.5 Janssen Pharmaceuticals Recent Development
13.10 Sunovion Pharmaceuticals
13.10.1 Sunovion Pharmaceuticals Company Details
13.10.2 Sunovion Pharmaceuticals Business Overview
13.10.3 Sunovion Pharmaceuticals Epilepsy Therapeutic Introduction
13.10.4 Sunovion Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2015-2020)
13.10.5 Sunovion Pharmaceuticals Recent Development
13.11 Bausch Health
10.11.1 Bausch Health Company Details
10.11.2 Bausch Health Business Overview
10.11.3 Bausch Health Epilepsy Therapeutic Introduction
10.11.4 Bausch Health Revenue in Epilepsy Therapeutic Business (2015-2020)
10.11.5 Bausch Health Recent Development
13.12 Sanofi S.A
10.12.1 Sanofi S.A Company Details
10.12.2 Sanofi S.A Business Overview
10.12.3 Sanofi S.A Epilepsy Therapeutic Introduction
10.12.4 Sanofi S.A Revenue in Epilepsy Therapeutic Business (2015-2020)
10.12.5 Sanofi S.A Recent Development
13.13 Takeda
10.13.1 Takeda Company Details
10.13.2 Takeda Business Overview
10.13.3 Takeda Epilepsy Therapeutic Introduction
10.13.4 Takeda Revenue in Epilepsy Therapeutic Business (2015-2020)
10.13.5 Takeda Recent Development
13.14 Eisai
10.14.1 Eisai Company Details
10.14.2 Eisai Business Overview
10.14.3 Eisai Epilepsy Therapeutic Introduction
10.14.4 Eisai Revenue in Epilepsy Therapeutic Business (2015-2020)
10.14.5 Eisai Recent Development
13.15 F. Hoffmann-La Roche
10.15.1 F. Hoffmann-La Roche Company Details
10.15.2 F. Hoffmann-La Roche Business Overview
10.15.3 F. Hoffmann-La Roche Epilepsy Therapeutic Introduction
10.15.4 F. Hoffmann-La Roche Revenue in Epilepsy Therapeutic Business (2015-2020)
10.15.5 F. Hoffmann-La Roche Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Epilepsy Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by Epilepsy Therapeutic Revenue
Table 3. Ranking of Global Top Epilepsy Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Epilepsy Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of First Generation
Table 6. Key Players of Second Generation
Table 7. Global Epilepsy Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Epilepsy Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Epilepsy Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Epilepsy Therapeutic Market Share by Regions (2015-2020)
Table 11. Global Epilepsy Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Epilepsy Therapeutic Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Epilepsy Therapeutic Market Growth Strategy
Table 17. Main Points Interviewed from Key Epilepsy Therapeutic Players
Table 18. Global Epilepsy Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 19. Global Epilepsy Therapeutic Market Share by Players (2015-2020)
Table 20. Global Top Epilepsy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epilepsy Therapeutic as of 2019)
Table 21. Global Epilepsy Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Epilepsy Therapeutic Product Solution and Service
Table 24. Date of Enter into Epilepsy Therapeutic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 27. Global Epilepsy Therapeutic Market Size Share by Type (2015-2020)
Table 28. Global Epilepsy Therapeutic Revenue Market Share by Type (2021-2026)
Table 29. Global Epilepsy Therapeutic Market Size Share by Application (2015-2020)
Table 30. Global Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 31. Global Epilepsy Therapeutic Market Size Share by Application (2021-2026)
Table 32. North America Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 34. North America Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 35. North America Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 36. North America Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 37. North America Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 38. Europe Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 40. Europe Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 42. Europe Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 44. China Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 45. China Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 46. China Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 47. China Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 48. China Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 49. China Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 50. Japan Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 52. Japan Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 54. Japan Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 58. Southeast Asia Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 60. Southeast Asia Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 62. India Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 63. India Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 64. India Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 65. India Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 66. India Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 67. India Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Epilepsy Therapeutic Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Epilepsy Therapeutic Market Share (2019-2020)
Table 70. Central & South America Epilepsy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Epilepsy Therapeutic Market Share by Type (2015-2020)
Table 72. Central & South America Epilepsy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Epilepsy Therapeutic Market Share by Application (2015-2020)
Table 74. Abbott Laboratories Company Details
Table 75. Abbott Laboratories Business Overview
Table 76. Abbott Laboratories Product
Table 77. Abbott Laboratories Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 78. Abbott Laboratories Recent Development
Table 79. GlaxoSmithKline Plc Company Details
Table 80. GlaxoSmithKline Plc Business Overview
Table 81. GlaxoSmithKline Plc Product
Table 82. GlaxoSmithKline Plc Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 83. GlaxoSmithKline Plc Recent Development
Table 84. UCB Company Details
Table 85. UCB Business Overview
Table 86. UCB Product
Table 87. UCB Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 88. UCB Recent Development
Table 89. Cephalon Company Details
Table 90. Cephalon Business Overview
Table 91. Cephalon Product
Table 92. Cephalon Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 93. Cephalon Recent Development
Table 94. Johnson & Johnson Company Details
Table 95. Johnson & Johnson Business Overview
Table 96. Johnson & Johnson Product
Table 97. Johnson & Johnson Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 98. Johnson & Johnson Recent Development
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Product
Table 102. Pfizer Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 103. Pfizer Recent Development
Table 104. Novartis AG Company Details
Table 105. Novartis AG Business Overview
Table 106. Novartis AG Product
Table 107. Novartis AG Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 108. Novartis AG Recent Development
Table 109. Abbvie Business Overview
Table 110. Abbvie Product
Table 111. Abbvie Company Details
Table 112. Abbvie Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 113. Abbvie Recent Development
Table 114. Janssen Pharmaceuticals Company Details
Table 115. Janssen Pharmaceuticals Business Overview
Table 116. Janssen Pharmaceuticals Product
Table 117. Janssen Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 118. Janssen Pharmaceuticals Recent Development
Table 119. Sunovion Pharmaceuticals Company Details
Table 120. Sunovion Pharmaceuticals Business Overview
Table 121. Sunovion Pharmaceuticals Product
Table 122. Sunovion Pharmaceuticals Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 123. Sunovion Pharmaceuticals Recent Development
Table 124. Bausch Health Company Details
Table 125. Bausch Health Business Overview
Table 126. Bausch Health Product
Table 127. Bausch Health Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 128. Bausch Health Recent Development
Table 129. Sanofi S.A Company Details
Table 130. Sanofi S.A Business Overview
Table 131. Sanofi S.A Product
Table 132. Sanofi S.A Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 133. Sanofi S.A Recent Development
Table 134. Takeda Company Details
Table 135. Takeda Business Overview
Table 136. Takeda Product
Table 137. Takeda Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 138. Takeda Recent Development
Table 139. Eisai Company Details
Table 140. Eisai Business Overview
Table 141. Eisai Product
Table 142. Eisai Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 143. Eisai Recent Development
Table 144. F. Hoffmann-La Roche Company Details
Table 145. F. Hoffmann-La Roche Business Overview
Table 146. F. Hoffmann-La Roche Product
Table 147. F. Hoffmann-La Roche Revenue in Epilepsy Therapeutic Business (2015-2020) (Million US$)
Table 148. F. Hoffmann-La Roche Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Epilepsy Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. First Generation Features
Figure 3. Second Generation Features
Figure 4. Global Epilepsy Therapeutic Market Share by Application: 2020 VS 2026
Figure 5. Hospital Pharmacies Case Studies
Figure 6. Retail Pharmacies Case Studies
Figure 7. Online Pharmacies Case Studies
Figure 8. Epilepsy Therapeutic Report Years Considered
Figure 9. Global Epilepsy Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Epilepsy Therapeutic Market Share by Regions: 2020 VS 2026
Figure 11. Global Epilepsy Therapeutic Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Epilepsy Therapeutic Market Share by Players in 2019
Figure 14. Global Top Epilepsy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epilepsy Therapeutic as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Epilepsy Therapeutic Revenue in 2019
Figure 16. North America Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Epilepsy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
癲癇治療薬の世界市場（～2026年） Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epileps…- 小児てんかん治療薬の世界市場（～2026年） Epilepsy is one of the most common and challenging neurologic disorders affecting children. Pediatric epilepsies present particular challenges, including correct diagnoses, comorbidities and interactions with developmental processes in the brain. Market Analysis and Insights: Global Pediatric Epilep…
- 癲癇診断・治療の世界市場（～2026年） Epilepsy is a neurological disorder affecting the central nervous system. In this medical condition, the brain exhibits abnormal activity, which results in periods of unusual behavior or seizures and sometimes, loss of awareness. Temporary confusion, anxiety, uncontrollable jerking movements of the …
- 副鼻腔治療薬の世界市場（～2026年） Market Analysis and Insights: Global Sinus Therapeutic Drug Market The global Sinus Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the repo…
- 眼科用治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ophthalmic Therapeutic Drugs Market The global Ophthalmic Therapeutic Drugs market size is projected to reach US$ 16740 million by 2026, from US$ 15860 million in 2020, at a CAGR of 5.2%% during 2021-2026. Global Ophthalmic Therapeutic Drugs Scope and Market Size…